Belite Bio Inc - Adr (BLTE)
$43.2
+2.1
(+5.11%)▲
Performance
- $40.99$43.45$43.20
5.12%
Downside
Day's Volatility :5.66%
Upside
0.58%
- $11.00$48.60$43.20
74.54%
Downside
52 Weeks Volatility :77.37%
Upside
11.11%
Returns
| Period | Belite Bio Inc - Adr | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -3.79% | -2.2% | 0.0% |
6 Months | 10.12% | 9.8% | 0.0% |
1 Year | 61.19% | 5.4% | 0.5% |
3 Years | 194.88% | 14.3% | -21.1% |
Highlights
Market Capitalization | 1.1B |
Book Value | $3.1 |
Earnings Per Share (EPS) | -1.19 |
Wall Street Target Price | 56.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -28.5% |
Return On Equity TTM | -47.95% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -31.5M |
Diluted Eps TTM | -1.19 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.77 |
EPS Estimate Next Year | -0.82 |
EPS Estimate Current Quarter | -0.3 |
EPS Estimate Next Quarter | -0.25 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 30.79%
Technicals Summary
Sell
Neutral
Buy
Belite Bio Inc - Adr is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Belite Bio Inc - Adr | 8.05% | 10.12% | 61.19% | 194.88% | 194.88% |
 Moderna, Inc. | 18.95% | 73.44% | -5.12% | -22.12% | 361.25% |
 Regeneron Pharmaceuticals, Inc. | 1.97% | 14.97% | 27.24% | 91.91% | 178.01% |
 Novo Nordisk A/s | -3.46% | 21.74% | 46.11% | 231.67% | 415.39% |
 Vertex Pharmaceuticals Incorporated | -0.78% | 3.97% | 16.56% | 88.16% | 129.5% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Belite Bio Inc - Adr | NA | NA | NA | -0.77 | -0.48 | -0.28 | NA | 3.1 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Belite Bio Inc - Adr | Buy | $1.1B | 194.88% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 361.25% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 178.01% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 415.39% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 129.5% | 28.81 | 36.68% |
Institutional Holdings
Armistice Capital, LLC
0.12%Morgan Stanley - Brokerage Accounts
0.08%State Street Corporation
0.06%Cubist Systematic Strategies, LLC
0.06%Marshall Wace Asset Management Ltd
0.05%JPMorgan Chase & Co
0.05%
Company Information
belite bio inc is a san diego based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes. developed from our anti-rbp4 technology platform, our lead candidate, lbs-008, is currently in a phase i clinical trial for dry age-related macular degeneration and its juvenile form, stargardt disease. lbs-008 has received orphan drug status in the us and europe, as well as rare pediatric disease status in the us.
Organization | Belite Bio Inc - Adr |
Employees | 20 |
CEO | Dr. Yu-Hsin Lin M.B.A., Ph.D. |
Industry | Healthcare |
